Compound News and Research

RSS

Onyx Pharmaceuticals acquires license option on novel JAK2 inhibitors from S*BIO

Onyx Pharmaceuticals, Inc. has announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore.

6 Jan 2009

Clioquinol - gastrointestinal drug could become anti-aging treatment

Recent animal studies have shown that clioquinol – an 80-year old drug once used to treat diarrhea and other gastrointestinal disorders – can reverse the progression of Alzheimer's, Parkinson's and Huntington's diseases.

6 Jan 2009

Novel compound F15845 shows promise for angina

A compound designed to prevent chest pains in heart patients has shown promising results in animal studies, say scientists.

6 Jan 2009

Extract from grapes kills lab leukemia cells, proving value of natural compounds

An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky.

1 Jan 2009

SRS microscopy helps track molecules and drugs in live cells

A new type of highly sensitive microscopy developed by researchers at Harvard University could greatly expand the limits of modern biomedical imaging, allowing scientists to track the location of minuscule metabolites and drugs in living cells and tissues without the use of any kind of fluorescent labeling.

18 Dec 2008

Scientists coax bright white light from zinc oxide

Duke University and United States Army scientists have found that a cheap and nontoxic sunburn and diaper rash preventative can be made to produce brilliant light best suited to the human eye.

18 Dec 2008

Compound from olive-skin pomace protects against colon-cancer

Researchers from the University of Granada and the University of Barcelona have shown that treatment with maslinic acid, a triterpenoid compound isolated from olive-skin pomace, results in a significant inhibition of cell proliferation and causes apoptotic death in colon-cancer cells.

18 Dec 2008

Human Pheromone Sciences files patent for mood enhancing compound derived from sea coral

Human Pheromone Sciences, Inc. has announced that it has filed a Comprehensive Patent Application with the U.S. Patent and Trademark Office for the use of an innovative and previously undeveloped compound with its origin in sea coral, which has significant emotional impacts on both men and women, enhancing feelings of positive social relationships, personal well-being and social attraction.

17 Dec 2008

Researchers hunt for new drugs for Leishmaniasis

Hundreds of millions of people, mainly in developing countries, are disabled by infectious diseases, according to the World Health Organization.

16 Dec 2008

Both theories about human cellular aging supported by new research

Aging yeast cells accumulate damage over time, but they do so by following a pattern laid down earlier in their life by diet as well as the genes that control metabolism and the dynamics of cell structures such as mitochondria, the power plants of cells.

16 Dec 2008

Receptor for prostaglandin-E2 plays key role in atherosclerosis development

Atherosclerosis - a disease that includes the buildup of fatty, cholesterol-laden lumps of cells inside the artery wall - is the underlying cause of heart attacks and strokes.

15 Dec 2008

New therapeutic targets for malaria

Scientists working on a common antimicrobial compound with antimalarial activity have discovered a range of new therapeutic strategies to combat malaria.

10 Dec 2008

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

Experimental drug successfully blocks mutation in bone marrow cancers

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

10 Dec 2008

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AstraZeneca and Targacept, Inc. havey announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

10 Dec 2008

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008